Security key
297584112
Estrella Immunopharma, Inc. - *W EXP 09/29/202 (ESLAW)
CUSIP: 297584112
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / *W EXP 09/29/202
- Total 13F shares
- 461,476
- Total 13F value
- $349,082
- Share change
- -5,653
- SEC-reported price per share
- $0.05
- Number of holders
- 8
- Value change
- +$38,943
- Number of buys
- 1
- Number of sells
- 4
Report period
Q4 2025
Institutions
8
Top holders
8
ESLAW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Estrella Immunopharma, Inc. SEC filings
Estrella Immunopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 297584112
Recent filing periods:
Ownership snapshot
Top reported holders of ESLAW - Estrella Immunopharma, Inc. - *W EXP 09/29/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Eureka Therapeutics, Inc.
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
0/15
Latest evidence
30 Sep 2025
3/4/5
13F
Highest disclosed value: $499,456
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD GROUP INC has the largest disclosed position value at $499.5K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Disclosed position value
Top 5
VANGUARD GROUP INC
$499.5K
BOOTHBAY FUND MANAGEMENT, LLC
$218.4K
GEODE CAPITAL MANAGEMENT, LLC
$120.8K
CITADEL ADVISORS LLC
$59.6K
UBS Group AG
$58K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Eureka Therapeutics, Inc. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
25,277,831 shares
|
— | 29 Sep 2023 |
| TradeUP Acquisition Sponsor LLC |
3/4/5
Former 10% owner
|
—
denominator unverified
|
—
1,145,760 shares
|
— | 29 Sep 2023 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$499,456
419,711 shares
|
— | 30 Sep 2025 |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$218,384
189,899 shares
|
— | 30 Sep 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$120,772
101,490 shares
|
— | 30 Sep 2025 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$59,645
50,122 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
8
Shares
461,476
Rows available
8
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
12
Q4 2025 holders
8
Holder diff
-4
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend